Noprex (Buprenorphine)

Buprenorphine, the active ingredient in Noprex, is an opioid analgesic presented as a transdermal patch for transdermal use. It provides continuous pain relief for moderate to severe chronic pain, including cancer‑related pain, in adult patients requiring long‑term management.

GNH USA supplies Noprex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and offering reliable global distribution with dedicated regulatory support.

Buprenorphine is used for pain management in conditions that require opioid therapy.

- Moderate to severe chronic non‑cancer pain: provides continuous analgesia over several days. - Cancer‑related pain: alleviates persistent pain in oncology patients. - Chronic postoperative pain (when indicated): maintains steady plasma levels to reduce breakthrough pain.

Adverse reactions may occur with buprenorphine transdermal therapy.

Common Side Effects: - Nausea - Constipation - Dizziness - Headache - Somnolence - Skin irritation at the patch site

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Opioid dependence or withdrawal syndrome - Anaphylactic or severe allergic reaction - QT interval prolongation

When prescribing buprenorphine transdermal patches, consider the following precautions.

- Dose titration: start with the lowest effective patch strength and adjust as needed. - Patient monitoring: regularly assess pain control and signs of opioid excess. - Contraindications: avoid use in patients with known hypersensitivity to buprenorphine or patch components. - Pregnancy and lactation: use only if the therapeutic benefit justifies potential risk. - Drug interactions: review concomitant CNS depressants and CYP3A4 modulators. - Store at room temperature: keep in the original pouch, protect from moisture and heat.

Buprenorphine may interact with other medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Full opioid agonists (e.g., morphine, fentanyl): additive risk of respiratory depression. - Benzodiazepines and other CNS depressants: increased sedation and respiratory compromise. - Monoamine oxidase inhibitors (MAOIs): potential for severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise buprenorphine plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic efficacy. - Alcohol: can enhance central nervous system depression.